Business Wire

Bynder Acquires EMRAYS to Revolutionize DAM User Experience With AI-Powered Innovation

19.9.2023 13:23:00 EEST | Business Wire | Press release

Share

Bynder, the market-leading digital asset management (DAM) platform has today announced the acquisition of EMRAYS, a specialist provider of AI search solutions for DAM.

The acquisition further elevates Bynder’s widely recognised user experience and will improve asset findability for Bynder DAM users. It builds on Bynder’s existing investments in AI and reaffirms the company’s commitment to helping customers conquer the complexity and chaos of proliferating content with the most powerful, intuitive, and richly integrated DAM platform.

With these new capabilities, DAM admins can reduce or eliminate the time and effort needed to manage assets, reduce costs associated with management of their DAM, while improving the speed and relevancy associated with the discovery of assets. EMRAYS enables Bynder customers to further benefit from their market leading user experience, building on their market leading user adoption, especially in large enterprise deployments.

EMRAYS was an existing partner whose technology was built specifically for Bynder DAM. The technology is already adopted within a number of customer accounts and is helping these brands to deliver even better content experiences to their customers.

For brands grappling with the challenges of managing content at scale, EMRAYS similarity search, search by image, text in image search, and duplicate finder impacts the heart of their content operations, allowing teams to find, reuse and deliver more relevant content, quicker and more effectively.

Siemens Healthineers use the Bynder DAM platform across 30,000 users, and already benefit from EMRAYS capabilities. André Kögler, Head of Digital Strategy & Tools, Creative Services said: “EMRAYS AI search enables us to find images and content faster, improving efficiency in our processes. In addition, the enhanced organization features help ensure the content in our Bynder DAM is consistent and high quality.”

Bob Hickey, CEO of Bynder, said: “We are excited to be welcoming the EMRAYS team to Bynder. This announcement comes off the back of recent investments in bringing generative AI capabilities to market.

“Marketing teams across the globe continue to be challenged with the need to manage and distribute a growing volume of targeted content. The acquisition of EMRAYS will help our customers automate the management of this. Like many of our recent AI developments, this acquisition is further proof of Bynder’s commitment to continued innovation and market leadership in the DAM category. The combination of product and people will enable us to accelerate our AI roadmap and deliver additional value to our customers faster.”

Cliff Crosbie, CEO and Co-Founder of EMRAYS said: “AI within DAM has become a strategic ally for marketers seeking to streamline content operations and improve customer experiences. The interest and demand we’ve had from customers to implement our AI technology within the Bynder platform has fueled this partnership and subsequent acquisition. The value that customers receive from EMRAYS capabilities already is invaluable, as marketers overcome content creation challenges and achieve greater efficiency.

“We’re excited about this acquisition and look forward to innovating with Bynder on their AI roadmap.”

For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/

-ENDS-

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Manisha Mehta
manisha.mehta@bynder.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f

Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye